The five-year grant, led by Keith McCrae, MD, and Alok Khorana, MD, supports the creation of a new risk assessment tool to better predict which cancer patients will develop treatment-related thrombosis.
Findings from a mouse model provide support for a new drug class that acts on gut microbes to reduce platelet responsiveness and thrombosis risk without promoting bleeding or antibiotic resistance.
An FDA advisory panel just recommended approval of what may be the nation’s first bioresorbable stent. Here’s why an ABSORB III trial investigator wasn’t surprised that interim results didn’t find it superior to a standard DES.
Yet another cardiometabolic effect has been linked to the gut microbial metabolite TMAO: increased thrombotic risk stemming from platelet hyperreactivity. The lead Cleveland Clinic researcher discusses the implications.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic oncologist Alok Khorana, MD, discusses the appropriateness of cancer screenings in the wake of unprovoked thromboembolisms in a NEJM Editorial.
New analysis of the phase III CATCH trial of blood-thinning treatments identifies two clinical indicators for recurrent venous thromboembolism: tumor venous compression and hepatobiliary cancer.
New developments promise further progress against restenosis and thrombosis after percutaneous vascular interventions. Cleveland Clinic interventionalists share perspectives on three leading developments.
Specialized team focuses on research, reducing costs
The Khorana score, named for its developer, Cleveland Clinic hematologist/oncologist Alok Khorana, MD, effectively forecasts cancer patients’ blood clotting risk based on a collection of simple variables — type of cancer, body mass index and complete blood count.